EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

EyePoint Pharmaceuticals Inc Phase 1 DAVIO Trial Of EYP-1901 Results Conference Call Transcript

Nov 13, 2021 / 05:00PM GMT
Operator

Good day, ladies and gentlemen, and welcome to EyePoint Pharmaceuticals Data Call at American Academy of Ophthalmology. (Operator Instructions)

I would now like to turn the conference over to your first speaker today, Mr. George Elston, CFO. Sir, the floor is yours.

George O. Elston
EyePoint Pharmaceuticals, Inc. - CFO & Head of Corporate Development

Thank you, and thank you all for joining us on today's conference call to discuss our positive top line safety and efficacy results from the Phase I DAVIO trial evaluating EYP-1901 for the treatment of Wet AMD.

I am George Elston, the CFO of EyePoint Pharmaceuticals, and with me today is Nancy Lurker, President and Chief Executive Officer; Dr. Jay Duker, Chief Operating Officer; Dr. Dario Paggiarino, Chief Medical Officer; and Dr. Carl Regillo, KOL and Chairman of the company's Scientific Advisory Board.

Earlier this morning, we issued a press release detailing our results. We are using slides to accompany our remarks today, which will be found in the Investor Relations tab on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot